If they can sell BlinkLab for $200M like ResApp .... sign me up. Some people were not happy with acquisition as they invested in RAP when the stock was doing the hockey stick chart and paid 40c-50c. At some stage RAP had a market cap of almost 500M, that's before they started FDA studies that ultimately failed. Yet Pfizer gave them a descent check just for the tech component.... that tells you about potential upside in these companies
The float, page-87
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
